Curaleaf International, a subsidiary of Curaleaf Holdings Inc., has received EU medical device certification for its handheld liquid inhalation device, developed in partnership with Jupiter Research LLC, a subsidiary of TILT Holdings Inc. This marks the introduction of Europe’s first device designed for precise administration of medical cannabis, certified under Regulation (EU) 2017/745.
The inhalation device is classified as a Class IIa medical device, meeting stringent European regulations. It features a magnetic snap-in cartridge and a rechargeable power supply, ensuring consistent cannabinoid delivery. This certification comes after a thorough assessment of the device’s technical documentation by a recognized EU Notified Body, affirming its quality, safety, and clinical effectiveness.
The certification opens avenues for Curaleaf International to market the device across various global regions, including European countries, the United Kingdom, Canada, and parts of Australasia. Health care professionals will soon be able to recommend this new device to their patients as an accurate and discreet treatment option.
Boris Jordan, Chairman and CEO of Curaleaf, stated, “Achieving EU medical certification is a clear indication that medical cannabis innovation is becoming more integrated into global health care. We are excited to offer a device that adheres to high safety and quality standards, providing new treatment options for patients and health care providers.”
Tim Conder, CEO of TILT, emphasized the significance of this collaboration, noting that it extends their successful partnership in the U.S. He added, “This certification affirms the strength of our engineering and research capabilities and sets a new standard in the industry.”
With this development, Curaleaf International reinforces its commitment to expanding access to high-quality cannabis treatments across Europe and other international markets.
English 
Spanish 
German 
Czech